A study of more than 11,000 U.S. adults suggests an association between acid-suppression therapy, including PPIs, H2RAs, and generic antacids, and an increased risk of migraine and severe headaches compared with people who do not take these medications. The risk was 70% higher for those using PPIs, 40% higher for those taking H2RAs, and 30% higher for generic antacids.

Clinicians continue to treat resistant gram-negative infections with older, generic antibiotics that are considered to be less effective and less safe, even though FDA has approved seven next-generation gram-negative antibiotics between 2014 and 2019.